SLC5A2 and hydrops fetalis: In the EMPEROR-PRESERVED trial, prescription of sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin demonstrated a reduction in risk of composite cardiovascular death or total HF hospitalization in HF with LVEF > 40% (4).